Top

Published in:

01-06-2010 | Original Article

Enhanced Delivery of Erythropoietin Across the Blood–Brain Barrier for Neuroprotection Against Ischemic Neuronal Injury

Authors: Feng Zhang, Juan Xing, Anthony Kian-Fong Liou, Suping Wang, Yu Gan, Yumin Luo, Xuming Ji, R. Anne Stetler, Jun Chen, Guodong Cao

Published in: Translational Stroke Research | Issue 2/2010

Abstract

Due to limited penetration of the blood–brain barrier (BBB), many therapeutic agents in clinical use require higher doses in order to reach effective concentrations in brain. In some instances, these high doses elicit severe side effects. In the case of erythropoietin (EPO), an established neuroprotectant against ischemic brain injury, its low BBB permeability requires such a high therapeutic dose that it can induce dangerous complications such as polycythemia and secondary stroke. The purpose of this study is to generate a modified EPO that has increased facility crossing the BBB without losing its neuroprotective element. We have engineered a fusion protein (EPO-TAT) by tagging a protein transduction domain derived from HIV trans-acting activator of transcription (TAT) to the EPO protein. This sequence enhanced the capacity of EPO to cross the BBB in animals at least twofold when intraperitoneally administered and up to fivefold when intravenously administered. In vitro experiments showed that this EPO fusion protein retained all its protective properties against neuronal death elicited by oxygen–glucose deprivation and N-methyl-d-aspartate insults. The needed therapeutic dose of the EPO-TAT was decreased by ∼tenfold compared to that of regular EPO to achieve equivalent neuroprotection in terms of reducing volume of infarction induced by middle cerebral artery occlusion in mice. Our results support the approach of using a protein transduction domain coupled to therapeutic agents. In this way, not only can the therapeutic doses be lowered but also agents without BBB permeability may now be available for clinical applications.

Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97(19):10526–10531PubMedCrossRef

Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M et al (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95(8):4635–4640PubMedCrossRef

Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8(8):495–505PubMed

Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6(6):484–494PubMedCrossRef

Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M (2001) Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J Cereb Blood Flow Metab 21(7):857–864PubMedCrossRef

Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4(8):459–460PubMedCrossRef

Wolf RF, Peng J, Friese P, Gilmore LS, Burstein SA, Dale GL (1997) Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost 78(6):1505–1509PubMed

Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK (2003) Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98(7):1514–1520PubMedCrossRef

Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR et al (2002) In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 22(13):5423–5431PubMed

10.

Kilic U, Kilic E, Dietz GP, Bahr M (2003) Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 34(5):1304–1310PubMedCrossRef

11.

Yin W, Cao G, Johnnides MJ, Signore AP, Luo Y, Hickey RW et al (2006) TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF. Neurobiol Dis 21(2):358–371PubMedCrossRef

12.

Chen J, Nagayama T, Jin K, Stetler RA, Zhu RL, Graham SH et al (1998) Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia. J Neurosci 18(13):4914–4928PubMed

13.

Frankmann SP (1986) A technique for repeated sampling of CSF from the anesthetized rat. Physiol Behav 37(3):489–493PubMedCrossRef

14.

Cao G, Pei W, Lan J, Stetler RA, Luo Y, Nagayama T et al (2001) Caspase-activated DNase/DNA fragmentation factor 40 mediates apoptotic DNA fragmentation in transient cerebral ischemia and in neuronal cultures. J Neurosci 21(13):4678–4690PubMed

15.

Cao G, Clark RS, Pei W, Yin W, Zhang F, Sun FY et al (2003) Translocation of apoptosis-inducing factor in vulnerable neurons after transient cerebral ischemia and in neuronal cultures after oxygen-glucose deprivation. J Cereb Blood Flow Metab 23(10):1137–1150PubMedCrossRef

16.

Chong ZZ, Maiese K (2007) Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol 150(7):839–850PubMedCrossRef

17.

Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M et al (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305(5681):239–242PubMedCrossRef

18.

Ranchon Cole I, Bonhomme B, Doly M (2007) Pre-treatment of adult rats with high doses of erythropoietin induces caspase-9 but prevents light-induced retinal injury. Exp Eye Res 85(6):782–789PubMedCrossRef

19.

Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE (2007) Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res 61(6):671–675PubMed

20.

Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA (2004) Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate 85(2):138–144PubMedCrossRef

21.

Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A et al (2002) Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA 99(8):5627–5631PubMedCrossRef

22.

Doeppner TR, Nagel F, Dietz GP, Weise J, Tonges L, Schwarting S et al (2009) TAT-Hsp70-mediated neuroprotection and increased survival of neuronal precursor cells after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 29(6):1187–1196PubMedCrossRef

23.

Zhou M, Xu W, Liao G, Bi X, Baudry M (2009) Neuroprotection against neonatal hypoxia/ischemia-induced cerebral cell death by prevention of calpain-mediated mGluR1alpha truncation. Exp Neurol 218(1):75–82PubMedCrossRef

24.

Xenocostas A, Cheung WK, Farrell F, Zakszewski C, Kelley M, Lutynski A et al (2005) The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 61(3):189–195PubMedCrossRef

25.

Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M et al (2003) Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 100(11):6741–6746PubMedCrossRef

26.

Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M et al (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 105(31):10925–10930PubMedCrossRef

27.

US Food and Drug Administration (2008) Early communication about an ongoing safety review epoetin alpha. US Food and Drug Administration

28.

Lieutaud T, Andrews PJ, Rhodes JK, Williamson R (2008) Characterization of the pharmacokinetics of human recombinant erythropoietin in blood and brain when administered immediately after lateral fluid percussion brain injury and its pharmacodynamic effects on IL-1beta and MIP-2 in rats. J Neurotrauma 25(10):1179–1185PubMedCrossRef

Title: Enhanced Delivery of Erythropoietin Across the Blood–Brain Barrier for Neuroprotection Against Ischemic Neuronal Injury
Authors: Feng Zhang
Juan Xing
Anthony Kian-Fong Liou
Suping Wang
Yu Gan
Yumin Luo
Xuming Ji
R. Anne Stetler
Jun Chen
Guodong Cao
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Translational Stroke Research / Issue 2/2010
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-010-0019-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Enhanced Delivery of Erythropoietin Across the Blood–Brain Barrier for Neuroprotection Against Ischemic Neuronal Injury

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development

Ccm1 Assures Microvascular Integrity During Angiogenesis

Beyond Neuroprotection to Brain Repair: Exploring the Next Frontier in Clinical Neuroscience to Expand the Therapeutic Window for Stroke

Magnesium Sulfate Treatment Improves Outcome in Patients with Subarachnoid Hemorrhage: A Meta-analysis Study

Effect of Hyperglycemia on Brain Penetrating Arterioles and Cerebral Blood Flow Before and After Ischemia/Reperfusion

Association Between Changes in Weight and Cerebral Arteries in Rats